Jackson Lab professor wins nearly $2M grant for investigating role of noncoding RNAs in cancer

NewsGuard 100/100 Score

The National Cancer Institute has awarded a three-year grant totaling $2,168,535 to Professor Yijun Ruan, Ph.D., of The Jackson Laboratory for Genomic Medicine, for his research into the role of noncoding RNAs in cancer and other diseases.

The best-known RNAs are those that manufacture proteins from the "blueprint" provided by DNA. But there are many kinds of non-coding RNAs (ncRNAs) that carry out other vital roles. In fact, there may be thousands of different kinds of ncRNAs yet to be discovered in the genome, each of which may have a specific role in healthy function or disease.

Using new technologies, Ruan and his lab will identify novel ncRNAs and the interactions between ncRNAs and their target DNAs. Since ncRNAs are associated with diseases such as cancers, such novel ncRNAs and their target DNAs have the potential to be diagnostic biomarkers and novel genomic therapeutic targets for disease.

"The study of ncRNAs' regulatory functions is becoming a new frontier in biology," Ruan says, "and we are developing new tools to study ncRNAs' functions, particularly in cancer biology. We are very pleased that NCI recognizes the potential of our strategy, and this funding will help us to do some exciting science and make important discoveries. We are very excited."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer